Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
CRG
AddedFeb 13, 2024
UpdatedJun 28, 2026
CRG

CRG

Operating

CRG LP: A global healthcare investment firm specializing in medical devices, bio-pharmaceuticals, and IT.

Location
Houston, TX, US
Founded
2003
Firm
Compare
Portfolio
Employees
Website

Investments

Calyxo
Calyxo

Total Raised

$97.2M

Rounds

4

Series C$32.7MJuly 2022
NavaDerm
NavaDerm

Total Raised

$30M

Rounds

1

Debt Financing$30MMay 2021
Treace Medical Concepts
Treace Medical Concepts
Public

Total Raised

$212.9M

Rounds

5

Debt Financing$50MAugust 2020
Aerin Medical
Aerin Medical

Total Raised

$190.5M

Rounds

8

Debt Financing$50MMay 2019
Harmony Biosciences
Harmony Biosciences
Public

Total Raised

$1.2B

Rounds

8

Debt Financing$200MMarch 2019
EyePoint
EyePoint
Public

Total Raised

$653.8M

Rounds

11

Debt Financing$60MFebruary 2019
HNI Healthcare
HNI Healthcare

Total Raised

$124.1M

Rounds

8

Private Equity$65MNovember 2018
Earlens
Earlens

Total Raised

$318.8M

Rounds

9

Series D$87MOctober 2018
Debt Financing$45MJune 2017
Series C$73MJune 2017
EndoGastric Solutions
EndoGastric Solutions

Total Raised

$380.2M

Rounds

22

Series I$40.6MJune 2018
Series Unknown$50MDecember 2015
Fast Pace Health
Fast Pace Health

Rounds

3

Private EquityJune 2018
Dynavax Technologies
Dynavax Technologies
Public

Total Raised

$1.4B

Rounds

19

Post Ipo Debt$175MFebruary 2018
Synergy Pharmaceuticals
Synergy Pharmaceuticals
Acquired

Total Raised

$407.2M

Rounds

6

Post Ipo Debt$300MSeptember 2017
Barricaid
Barricaid

Total Raised

$311.3M

Rounds

15

Series Unknown$17.9MDecember 2016
T2 Biosystems
T2 Biosystems
Acquired

Total Raised

$293.6M

Rounds

13

Post Ipo Debt$50MDecember 2016
Omeros
Omeros
Public

Total Raised

$972M

Rounds

24

Post Ipo Debt$125MNovember 2016
US WorldMeds
US WorldMeds

Total Raised

$15M

Rounds

3

Series UnknownJuly 2016
Iroko Pharmaceuticals
Iroko Pharmaceuticals
Acquired

Total Raised

$215M

Rounds

2

Debt Financing$140MJune 2016
Benvenue Medical
Benvenue Medical
Acquired

Total Raised

$232.5M

Rounds

10

Debt Financing$60MJanuary 2016
Realeve
Realeve

Total Raised

$136.2M

Rounds

6

Debt FinancingJanuary 2016
Avinger
Avinger
Public

Total Raised

$308.6M

Rounds

16

Post Ipo Equity$55MSeptember 2015
ViewRay
ViewRay
Public

Total Raised

$877.8M

Rounds

22

Post Ipo Debt$50MJune 2015
Outset Medical
Outset Medical
Public

Total Raised

$927M

Rounds

11

Debt Financing$45MJune 2015